Drug Discovery Approaches for Epigenetic Targets

Unveiling the Power of Epigenetics in Disease Etiology: Novel Therapeutic Opportunities Explored

The growing recognition of epigenetics’ pivotal role in cancer and various diseases has shed light on exciting possibilities for innovative therapies. Sygnature Discovery, in its pursuit of effective epigenetic drug discovery programs, has tackled challenges related to compound promiscuity in early stages by introducing a diverse array of methodologies. These encompass biochemical, biophysical, cellular target engagement, and biomarker approaches. This poster delves into two distinct epigenetic projects, showcasing breakthroughs in Deubiquitinase (DUB) and Bromodomain targets, each poised to shape the future of medical interventions.